AstraZeneca’s England approval of Enhertu signals wider access to cancer care, expanding NHS treatment options for eligible breast cancer patients.
A new MRI dye could help map tiny lung tumors and hidden metastases, offering earlier detection without radiation.
Lymphoma and its treatment can affect immune protection, making everyday infections a greater concern. Awareness, vaccination, monitoring and support can help patients navigate daily life.
GSK’s oncology buying spree gains momentum with a USD 750 million blood cancer bet targeting a potential new multiple myeloma treatment.
Glenmark's RYALTRIS brings dual-action therapy to Brazil, expanding treatment options for patients with moderate to severe allergic rhinitis symptoms.
Natco Pharma plans a ?1,300 crore rights issue as it builds funding capacity for M&A. The move adds to its QIP plan and ?3,500 crore cash reserves for strategic acquisitions.
AstraZeneca’s tozorakimab cuts COPD flare-ups by 29-34 percent, offering broad benefits across patients regardless of smoking status or eosinophil levels.
Lung disease pipeline advances as a cancer combo and PH-ILD drug deliver strong survival, pressure, and functional gains.
Biocon’s Brazil pact could lower pertuzumab costs for public patients by expanding biosimilar access and supporting local manufacturing.
A psychedelic drug could find potential beyond mental health, with researchers exploring psilocybin to prevent chemotherapy-related nerve damage.
.jpg)
, CDSCO.jpg)